TD Asset Management Inc Lowers Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Points

• TD Asset Management Inc reduced its stake in Janux Therapeutics by 16.7%, owning 65,636 shares after selling 13,200 shares recently.
• Institutional investors now hold 75.39% of Janux Therapeutics stock, with various funds significantly increasing their positions.
• Janux Therapeutics has reported a loss of $0.38 earnings per share, outperforming analysts' estimates, with a current consensus rating of "Buy."

TD Asset Management Inc cut its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 16.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 65,636 shares of the company's stock after selling 13,200 shares during the quarter. TD Asset Management Inc owned 0.11% of Janux Therapeutics worth $1,772,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. RA Capital Management L.P. increased its stake in shares of Janux Therapeutics by 13.1% during the fourth quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock worth $554,977,000 after purchasing an additional 1,200,000 shares during the period. FMR LLC boosted its position in Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after buying an additional 845,266 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Janux Therapeutics by 41.2% during the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock worth $190,617,000 after acquiring an additional 1,038,996 shares during the last quarter. Paradigm Biocapital Advisors LP increased its position in Janux Therapeutics by 46.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after acquiring an additional 1,115,412 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its stake in shares of Janux Therapeutics by 47.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after purchasing an additional 986,750 shares during the last quarter. Institutional investors own 75.39% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial started coverage on Janux Therapeutics in a research report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $91.89.

Janux Therapeutics Price Performance

Janux Therapeutics stock traded down $1.32 during trading hours on Wednesday, reaching $24.18. The company had a trading volume of 1,469,437 shares, compared to its average volume of 829,823. The company has a 50-day moving average price of $24.74 and a 200 day moving average price of $29.34. Janux Therapeutics, Inc. has a 12-month low of $22.48 and a 12-month high of $71.71. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -17.78 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. As a group, research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.